Who we are

CDI Labs Culture

Our bright and vibrant company DNA shapes the identity of our amazing culture. As the first biotech company to be founded on the island, Co-founder and then CEO, Ignacio Pino has recruited the best and brightest team from Mayagüez, Puerto Rico. We continue to cultivate an environment where our employees thrive, feel valued, and contribute their best. CDI Labs now operates from labs and offices in Baltimore, Toronto, and Mayagüez.

CDI LABS NEWS |

all news

About CDI Labs

CDI Labs is a specialized CRO and lab services proteomics company. Powered by cutting-edge synthetic biology platforms, we have generated the world’s largest collection of proteomes, and in doing so has built a team with deep proteomics bench expertise. Our team leverages our platforms and products to offer unique services that enable customers to decipher and characterize molecular interactions across entire proteomes.

Our solutions span basic research, discovery, validation and clinical deployment phases. Our services include: autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream validation.

Our services are performed under GLP/GMP quality standards and all results include comprehensive reports with custom bioinformatics services being available upon request.

Our Vision

Transform life science research by revealing how the molecular world interacts with proteomes. Help our customers translate new learnings into novel diagnostics and therapies that enhance the quality of life.

Our History

  • 2001
  • Co-founder Heng Zhu publishes his breakthrough paper featuring the first full eukaryotic proteome array with Michael Snyder
  • 2008
  • CDI Labs is founded to commercialize technologies 2008 created by the Johns Hopkins University School of Medicine
  • 2009
  • Future Director of Proteomic Sciences Shaohui Hu publishes on initial HuProt™ technology with Heng Zhu
  • 2010
  • First SBIR GrantSBIR Phase 1 Grant: Development of an Attenuated Babesia Vaccine for Cattle.
  • 2010
  • First STTR GrantSTTR Phase I grant awarded to produce and commercialize monoclonal antibodies used to study brain-expressed proteins that are implicated in human mental disorders. The antibodies were validated using CDI Labs' proprietary antigen microarrays.
  • 2011
  • Additional funding$800K note from the Puerto Rico Science Trust.
  • 2012
  • Major $13.5M NIH Roadmap grant to develop new reagents validated by HuProt™ microarrays
  • 2012
  • First publication of finalized HuProt™ technology
  • 2013
  • The first VirD™ prototype was developed in 2013 by CDI Labs' Director of Proteomic Sciences Shaohui Hu, working with Prashant Desai, Heng Zhu, and others at the Johns Hopkins University School of Medicine
  • 2015
  • CDI invited to attend White House Demo Day
  • 2016
  • Results of CDI’s work for the NIH Protein Capture Reagents Program are published in Nature Methods
  • 2016
  • Additional STTR GrantSTTR Phase 1 Grant: Validation of immune-based biomarkers for endometriosis.
  • 2016
  • Additional STTR GrantSTTR Phase 1 Grant: Monospecific monoclonal antibodies against human protein complexes on an interactome- wide scale.
  • 2018
  • Collaborators use HuProt™ to show that patients' pre-treatment autoantibody fingerprints can predict adverse events to cancer immunotherapy
  • 2019
  • Co-founder Heng Zhu publishes additional work on VirD™ membrane-embedded arrays
  • 2019
  • Antygen™ brand launched
  • 2019
  • mMabs™ brand launched
  • 2020
  • VirScan™ & HuScan™ technologies launchedFirst commercial application of phage display immunoprecipitation sequencing technologies.
  • 2020
  • Products for SARS-CoV-2 research developedRelease of SARS-COV-2 HuProt™ and funding from Puerto Rico Science Trust to develop tests for the virus that causes COVID-19.
  • 2023
  • BroadOak Capital Partners Invests in CDI Laboratories to Expand and Scale Antibody Biomarker Discovery Platforms
  • 2024
  • In March 2024, HuScan® PhIP-Seq register trademarked in the U.S.
  • 2024
  • In July 2024, VirScan® PhIP-Seq register trademarked in the U.S.
  • 2024
  • New VirScan®, HuScan® and MouseScan™ PhIP-Seq services by CDI Labs Canada launched on July 9

Biotech Companies in Puerto Rico

Puerto Rico has been home to a diverse range of biotech companies, leveraging the island's strategic location, skilled workforce, and favorable incentives. The biotech sector in Puerto Rico encompasses various areas, including pharmaceuticals, medical devices, research and development, and contract manufacturing. Many global pharmaceutical giants have established a presence on the island, attracted by its unique blend of regulatory advantages and proximity to key markets. CDI Labs, based in Mayagüez (with labs and offices in Baltimore and Toronto), is proud to be among the many notable biotech companies operating in Puerto Rico.